Clinical Trial Update: Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing the immunogenicity and reactogenicity of HBV-MPL vaccine and Engerix-B across two dosing schedules in healthy adults. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• HBV-MPL vaccine (HBV-MPL vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 2 | Status: COMPLETED